Idéal Investisseur
Français English
CAC 40 : Market open
7 994,93 pts
-0.51%


Last updated : 30/09/2026 - 12h51
🏠 Home   ➤    Stock news

Valneva stock among best SBF 120 performers, +23.5% in three months

The Lyon-based laboratory specializing in vaccines against infectious diseases is recovering ground on Wednesday, in an SBF 120 nearly balanced. The rebound occurs as the security remains caught between its two key moving averages and the quarterly momentum remains one of the most robust in the index.


Valneva stock among best SBF 120 performers, +23.5% in three months

A 2% rebound consolidating a quarterly gain of nearly 24%

Valneva rises 2.05% to €2.74 during the session, ranking among the best performers of the SBF 120 while the index declines 0.12%. This rebound is part of a quarterly gain of 23.79%, one of the most significant among index values. Over one week, the security shows a decline of 3.14%, indicating that the recent consolidation has not yet been fully erased, especially as the loss exceeds 40% over one year.

Today's movement is supported by a level at €2.66 which has held, with the price now at a comfortable distance from this floor. The next resistance is at €2.99, representing a potential of nearly 9% compared to current levels.

A mixed technical configuration, caught between 20-day and 50-day moving averages

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

The security is trading below its 20-day moving average (€2.84, down 3.45%), reflecting persistent short-term pressure, but remains above its 50-day MA at €2.63 (up 4.26%), which acts as an immediate safety net. The 200-day moving average at €3.10 remains significantly above the price (down 11.55%), underscoring that the path to recovering a long-term uptrend remains substantial. The RSI at 45 is neutral and signals no excess in either direction.

During the publication of H1 2026 results in August, the company had confirmed its 2026 outlook, with a target revenue of €147.5 million, emphasizing the expected improvement in margins in the second half following non-recurring items in the first half. The 20-day moving average at €2.84 represents the next level to cross for short-term momentum to turn favorably.



Sector Pharmacie et biotechnologies › Vaccins et laboratoires de recherche


Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext

Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 65,8 millions d'euros
  • Quarterly revenue: 65,8 millions d'euros
  • Revenue growth: -32,6 %
  • EBITDA: -39,8 millions d'euros
  • Net income: -63,3 millions d'euros
Guidance from the release
  • Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
  • Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
  • Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
  • Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
  • Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
  • Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
  • Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
  • Expected revenue: 147,5 millions d'euros

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours